Search

Categories

Pfizer Inc., the world?s largest drugmaker, on Wednesday said it abandoned an obesity drug known only by the designation CP-945,598 ? not specifically for safety concerns but because of ?changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval.?

?While confident in the safety of the compound, we believe that this is the appropriate decision based on all available information regarding this class of agents, as well as recent discussions with regulatory authorities,? Martin Mackay, president of Pfizer Global Research and Development, said in a statement.